Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA
A dvicenne announces positive opinion from the Fr ench Transparency Commission for its drug Sibnayal TM in dRTA. Sibnayal TM eligible for reimbursement by the French public health insurance system ASMR IV: Recognition of th e contribution of Sibnayal TM in the treatment of dRTA Paris, France, 20 December 2021– 7: 00 am CEST– Advicenne, a specialty pharmaceutical...